Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of CTP-543 in Healthy Volunteers
NCT05192369Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deuruxolitinib in alopecia areata (4 arms), sponsored by Concert Pharmaceuticals. Primary endpoint: TQT Analysis of QT/QTc Intervals at Day 10. Started Jan 2022; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05192369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192369.